Vitamin D, microbiota, and inflammatory bowel disease

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Inflammatory bowel disease (IBD) is a chronic intestinal inflammation that occurs because of uncontrolled immune responses to commensal microbiota in the gut and is estimated to affect over 6.8 million people globally. The composition of the gut microbiota and vitamin D status have been shown to impact IBD susceptibility. Patients with IBD have dysbiosis of the microbiome. Vitamin D is an important regulator of the immune system, and patients with IBD are frequently vitamin D deficient. Vitamin D interventions were able to resolve dysbiosis of the gut microbiota, induce regulatory T cells that suppress colitis, and reestablish immune homeostasis. There is no cure for IBD. Immunosuppressive drugs are used to suppress the intestinal inflammation in patients with IBD, but these drugs are extremely expensive and increase the risk of infection and cancer. Vitamin D supplementation could be a safe and effective adjunct to the therapies available to treat or prevent IBD.

Original languageEnglish (US)
Title of host publicationFeldman and Pike's Vitamin D
Subtitle of host publicationVolume Two: Disease and Therapeutics
PublisherElsevier
Pages1057-1073
Number of pages17
ISBN (Electronic)9780323913386
ISBN (Print)9780323913393
DOIs
StatePublished - Jan 1 2023

All Science Journal Classification (ASJC) codes

  • General Arts and Humanities

Cite this